January 14, 2025

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer, according to groundb...

The ASCO Post

January 14, 2025

Metformin May Impact Immunotherapy in NSCLC

Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Jou...

The ASCO Post

January 10, 2025

Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC

In a phase II trial reported in The Lancet Oncology, Heinzerling et al explored the efficacy of primary lung tumor stereotactic body radiotherapy (SBRT) followed by concurrent mediastinal chemotherapy...

The ASCO Post

January 07, 2025

Do Probiotics Impact Cancer Survival?

Moderate intake of dietary probiotics was inversely associated with cancer mortality,’ highlighting dose-specific effects seen in a 20-year NHANES analysis.

Conexiant

January 07, 2025

J&J Combo Beats Tagrisso on Survival

"Our expectation (is) that we're going to see an improvement in that median overall survival exceeding a year."

Reuters

December 26, 2024

Advancing Small-Cell Lung Cancer Care with Molecular Subtyping

Study of 195 SCLC patients emphasizes the diagnostic and therapeutic potential of 4 molecular subtypes and associated biomarkers.

Conexiant

December 17, 2024

FDA Rejects J&J’s Injectable Lung Cancer Drug

FDA declines to approve Johnson & Johnson's Rybrevant injectable for non-small cell lung cancer due to observations during pre-approval inspection unrelated to drug formulation, efficacy, or safety. J&J is working to resolve the issues.

Reuters

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post

September 21, 2023

NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC

An anti–PD-L1 monoclonal antibody in combination with other immuno-oncology agents may outperform treatment with the agent on its own in the neoadjuvant setting for patients with early-stage non–small...

The ASCO Post